Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hercules Technology Growth Capital
(NY:
HTGC
)
18.28
-0.01 (-0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hercules Technology Growth Capital
< Previous
1
2
3
4
5
6
7
Next >
Investing $100,000 in These 3 Ultra-High-Yield Dividend Stocks Could Bring $10,000 in Passive Income to Your Portfolio in 2024
January 05, 2024
Business development companies are a lucrative way to generate loads of passive income.
Via
The Motley Fool
PINES And QUIBS And PDs, Oh My - Minibonds Anyone?
December 23, 2023
Have you ever considered Minibonds for an income portfolio or your retirement plan? These are bonds that are traded just like stocks on the New York Stock Exchange, American Stock Exchange, or Nasdaq...
Via
Talk Markets
Topics
Bonds
Retirement
Exposures
Debt Markets
Pension
1 Ultra-High Dividend Yield Stock to Buy Hand Over Fist in 2024
December 15, 2023
Ares Capital has handily beaten the S&P 500 for several years.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
This Dividend Stock Has Returned 157% Over the Past 10 Years. You Can Buy It Today for Just $15
December 15, 2023
Hercules Technology Growth Capital makes high-yield loans to energy, life sciences, and technology businesses.
Via
The Motley Fool
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
December 14, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Don’t Forget BDCs For Stable, High-Yield Income
October 18, 2023
The Fed’s aggressive interest rate increases have been good for business development companies.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Where Hercules Capital Stands With Analysts
August 30, 2023
Via
Benzinga
Hercules Capital Receives SBA “Green Light” Letter to Submit Its Fourth SBIC License Application
November 09, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Hercules Capital Announces Upcoming Events for the Financial Community
November 08, 2023
From
Hercules Capital, Inc.
Via
Business Wire
You Can Buy All 4 of These Ultra-High Yield Dividend Stocks for Less Than $100
November 04, 2023
Looking for passive income? These stocks have proven track records of paying consistent dividends.
Via
The Motley Fool
Hercules Capital Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Why You Need To Be Buying BDCs Right Now
August 26, 2023
Via
Talk Markets
Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the Third Quarter 2023
October 31, 2023
From
Hercules Capital, Inc.
Via
Business Wire
This Ultra-High Dividend Stock Pays You Almost 12% to Own It. It Can Be Yours For Less Than $20
October 21, 2023
Hercules Capital has a rich history of dividend payments and outperforming the competition.
Via
The Motley Fool
Hercules Capital Announces Date for Release of Third Quarter 2023 Financial Results and Conference Call
October 12, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Hercules Capital Receives Reaffirmed Baa3 Investment Grade Credit and Corporate Rating from Moody’s Investors Service
October 04, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors
September 25, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Hercules Receives a BBB+ Reaffirmed Investment Grade Corporate Rating from Kroll Bond Rating Agency, Inc.
August 31, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 30, 2023
August 30, 2023
Via
Benzinga
The 3 Most Promising Pharma Stocks to Own Now
August 30, 2023
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
Via
InvestorPlace
When A Secondary Stock Offering Is Great News
August 14, 2023
A secondary stock offering comes with a sharp drop in a company’s stock price. Rapid price declines make investors nervous, wondering if the company is facing troubles.
Via
Talk Markets
RingCentral, Alteryx, International Flavors & Fragrances And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
August 08, 2023
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 08, 2023
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser...
Via
Benzinga
Hercules Capital, Inc. Prices Upsized Public Offering of Common Stock
August 07, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Hercules Capital, Inc. Announces Public Offering of Common Stock
August 07, 2023
From
Hercules Capital, Inc.
Via
Business Wire
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'
August 03, 2023
Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows:
Via
Benzinga
Hercules Capital Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Hercules Capital Increases Its Total Cash Distribution to $0.48 per Share for the Second Quarter 2023
August 01, 2023
From
Hercules Capital, Inc.
Via
Business Wire
Hercules Capital Announces Date for Release of Second Quarter 2023 Financial Results and Conference Call
July 10, 2023
From
Hercules Capital, Inc.
Via
Business Wire
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
July 05, 2023
Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.